# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ada Lovelace (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI031-SYN-TD
- Date: 1851-07-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Constance Whitley-Adeyemi, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Six-week review: bleeding and pain after palliative pelvic radiation, two weeks after the first cycle of chemotherapy with pembrolizumab. **S**

## History of present illness

Mrs. Lovelace returns four weeks after the consultation. The lung biopsy three weeks ago confirmed metastatic adenocarcinoma matching the cervical tumor. She completed five days of pelvic radiation, and the bleeding stopped within a week. She had the first cycle of carboplatin, paclitaxel and pembrolizumab two weeks ago, with nausea for two days. The constipation that brought her in a week ago settled within two days of the extra laxatives. Her average pelvic pain is 3 of 10 on long-acting morphine 15 mg twice a day, with a breakthrough dose on some days, and she is clear-headed in the mornings and working again. She feels low at times and finds it hard to sleep the night before treatment. She has no rash, diarrhea, or cough. **S**

| Element | Detail |
|---|---|
| Bleeding | Stopped a week after radiation |
| Pain | Average 3 of 10; breakthrough dose on some days; clear-headed |
| Chemotherapy | First cycle two weeks ago; nausea for two days |
| Bowels | Regular again since the sick visit |
| Mood | Low at times; PHQ-9 9 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Genitourinary | Negative | No bleeding; light discharge; no urinary burning |
| Gastrointestinal | Negative | Bowels regular; no diarrhea |
| Integumentary | Negative | No rash |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Positive | Low at times; poor sleep before treatment; no thoughts of self-harm |

5 systems reviewed. **S**

## Current medications

- Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain **S**
- Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow whole **S**
- Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911 **S**
- Senna 8.6 mg tablet, two tablets by mouth at night **S**
- Polyethylene glycol 3350, 17 g in water by mouth once or twice a day **S**
- Acetaminophen 500 mg tablet, two tablets by mouth three times a day **S**
- Pembrolizumab 200 mg intravenously every 3 weeks **S**
- Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cycles **S**
- Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedication **S**
- Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as needed **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 53.4 kg; BMI 19.6 kg/m². All vital signs are synthetic.

Hemoglobin: 9.8 g/dL (low); White cells: 4.1 10*3/uL; Neutrophils: 2.2 10*3/uL; Platelets: 236 10*3/uL; Creatinine: 0.7 mg/dL; ALT: 22 U/L; eGFR: 116 mL/min/1.73 m²; Pelvic pain, average over the past week (0 to 10): 3; PHQ-9: 9. All results are synthetic.

## Change since baseline

- Hemoglobin: 8.4 g/dL (low) at baseline, 9.8 g/dL (low) at this visit **S**
- White cells: 7.8 10*3/uL at baseline, 4.1 10*3/uL at this visit **S**
- Platelets: 412 10*3/uL (high) at baseline, 236 10*3/uL at this visit **S**
- Creatinine: 0.68 mg/dL at baseline, 0.7 mg/dL at this visit **S**
- ALT: 18 U/L at baseline, 22 U/L at this visit **S**
- eGFR: 116 mL/min/1.73 m² at baseline, 116 mL/min/1.73 m² at this visit **S**
- Pelvic pain, average over the past week (0 to 10): 7 at baseline, 3 at this visit **S**
- PHQ-9: 8 at baseline, 9 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert, not sedated; blood pressure 110/70, pulse 84, weight 53.4 kg |
| Mouth | No mucositis |
| Abdomen | Soft; mild suprapubic tenderness |
| Neurological | Sensation normal in the feet |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Metastatic cervical adenocarcinoma, on first-line chemotherapy with pembrolizumab** (C53.0). Stage IVB confirmed by the lung biopsy. Radiation has stopped the bleeding. Tolerating the first cycle: white cells 4.1, neutrophils 2.2, platelets 236, creatinine 0.70 mg/dL, ALT 22 U/L, so the second cycle can go ahead next week. No immune-related symptoms. **S**
   - Second cycle next week as planned.
   - Thyroid tests at six weeks, with the cycle 3 blood tests.
   - Restaging CT after four cycles.
2. **Cancer-related pelvic pain, controlled** (G89.3). Average 3 of 10 on long-acting morphine without sedation; she is working in the mornings. **S**
   - Continue long-acting morphine 15 mg twice a day and 5 mg as needed.
3. **Iron deficiency anemia** (D50.0). Hemoglobin 9.8 g/dL and rising, with the bleeding stopped. **S**
   - Ferritin 6 to 8 weeks after the second infusion.
4. **Long-term opioid therapy** (Z79.891). Safe use; no sedation; the bowel regimen restored after the sick visit. **S**
   - Laxatives every day while she takes morphine.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count (hemoglobin, white cells, neutrophils, platelets) | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 9.8 g/dL, white cells 4.1, neutrophils 2.2, platelets 236 |
| Laboratory | Creatinine, eGFR and ALT | Before each cycle | Completed today | Creatinine 0.70 mg/dL, eGFR 116, ALT 22 U/L |
| Laboratory | TSH and free T4 on pembrolizumab | Baseline, then every 6 weeks | Due | Baseline four weeks ago; next due in two weeks, six weeks from baseline |
| Laboratory | Ferritin after intravenous iron | 6 to 8 weeks after the infusions | Due | Due in two to four weeks |
| Examination | Vaginal bleeding and transfusion need | Every visit | Completed today | No bleeding since radiation |
| Examination | Immune-related adverse effects: rash, diarrhea, cough, fatigue | Every visit | Completed today | None |
| Examination | Peripheral neuropathy on paclitaxel | Before each paclitaxel cycle | Completed today | None |
| Imaging | Restaging CT of chest, abdomen and pelvis | Every 2 to 3 cycles during first-line therapy, then every 3 months | Due | After four cycles |
| Survey | Pain intensity (0 to 10) and function | Every visit | Completed today | Average 3 of 10 |
| Medication safety | Opioid adverse effects: sedation, confusion, nausea | Every visit | Completed today | No sedation; nausea for two days after the cycle |
| Medication safety | Bowel regimen and constipation | Every visit | Completed today | Constipation a week ago, resolved; daily laxatives |
| Medication safety | Naloxone, locked storage, one prescriber, prescription monitoring check | At each opioid change, and every 3 months | Up to date | Naloxone at home; locked storage |
| Medication safety | Signs of opioid use disorder | Every visit | Completed today | None |
| Survey | Depression screen (PHQ-9) and distress | At diagnosis and periodically | Completed today | PHQ-9 9, mild; offered and accepted psycho-oncology counseling |
| Referral | Specialist palliative care | Ongoing alongside cancer treatment | Completed today | Seen twice by the palliative care team |

## Goal progress

- Average pelvic pain at or below 3 of 10 without daytime sedation. Outcome by 1851-07-14: Average pain 3 of 10 after radiation, on long-acting morphine, without daytime sleepiness. **S**
- Bleeding controlled and hemoglobin above 10 g/dL without transfusion. In progress; target 1851-09-08. **S**
- A documented goals-of-care conversation and a named health care agent. In progress; target 1851-09-08. **S**
- Able to work on her mathematics for at least two hours most mornings. In progress; target 1851-10-20. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026), National Comprehensive Cancer Network
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021), New England Journal of Medicine
- Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024), American Society of Clinical Oncology
- Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, anemia monograph (2026), Aether Forge
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Schneider BJ, et al. J Clin Oncol 2021;39:4073-4126) (2021), American Society of Clinical Oncology

## Follow-up

- Second cycle next week. Preventive visit in five weeks. Fourteen-week review after the restaging CT. **S**
- Next scheduled visit 1851-08-18: periodic adult preventive visit. **S**
